
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 11, 2026
Lexicon announced its Jefferies conference appearance
Nasdaq: $LXRXCardiometabolic medicinesPhase 3 enrollment completeMilestone-dependent revenue
LXRX Stock Hub: Lexicon Pharmaceuticals News, ZYNQUISTA and SONATA-HCM
Lexicon’s September quarter showed why its clinical portfolio and its current business need separate measures: $10 million of $11.250 million in revenue came from one Novo Nordisk development milestone, while U.S. INPEFA sales contributed $1.181 million. The balance sheet held $183.203 million in cash and short-term investments at September 30. In the first quarter of 2027, management expects both the pivotal SONATA-HCM readout and a separate regulatory resubmission for type 1 diabetes, two events with different evidence and consequences. September financials · November 5 company guidance.
Full research report · PDF
Lexicon Pharmaceuticals ($LXRX), research updated November 18, 2026
16 pages on SONATA-HCM, ZYNQUISTA, licensing, September-quarter results, cash and financing. For personal use only: redistribution prohibited.
Next clinical and regulatory catalysts · company guidance
First quarter of 2027 · SONATA-HCM topline and ZYNQUISTA resubmission
The company expects the first results from its pivotal heart-muscle disease study in the same quarter that it plans to resubmit a New Drug Application (NDA) for ZYNQUISTA in type 1 diabetes. Lexicon had announced no specific day for either milestone as of November 17. November 5 guidance · Company announcements.
See the calendar for the November 18 investor event and earlier disclosures.
LXRX stock at a glance
Chart analysis · JC
Technical chart analysis of $LXRX with bull and bear scenarios on JC Just Charts.
Where Lexicon Pharmaceuticals stands now
Lexicon is selling INPEFA for its approved cardiovascular indications while pursuing two new uses for the same molecule, sotagliflozin. The business also earns contingent development payments on an obesity drug controlled by Novo Nordisk. Those sources of value mature on different timelines. Quarterly product sales offer the clearest measure of the franchise Lexicon has built itself. Clinical data and submitted applications will determine whether it can add to that franchise. INPEFA economics · The Novo and Viatris agreements.
Product revenue makes a small contribution to total operating costs. A quarter with a partner payment can look stronger even if prescribing and collections barely change. The schedule of such payments depends on milestones Lexicon cannot book ahead of time.
▲ The constructive case
Lexicon can use its capital to reach a controlled pivotal readout, submit a more complete safety package and prepare for commercialization if either route succeeds. Partner-funded development can broaden the portfolio without an equivalent increase in Lexicon’s trial spending.
▼ The cautious case
If the new indications require more evidence or take longer to reach patients, limited product revenue and prospective debt obligations leave shareholders exposed to the terms of future financing.
Latest Lexicon news
Nov 11, 2026
Lexicon announced its Jefferies conference appearance
On November 11 Lexicon announced that management was scheduled to participate in the London conference on November 18. The company listed a webcast and replay on its investor site.
Nov 9, 2026
Sotagliflozin poster studies examine clot formation and heart tissue
Lexicon reported two mechanistic studies from the American Heart Association meeting. Researchers measured clot formation outside the body using blood from healthy volunteers and assessed myocardial work in slices of human heart tissue. The results did not measure clinical outcomes in SONATA-HCM.
Nov 9, 2026
Lexicon CEO reports November 6 share purchases
A November 9 Form 4 filed by Michael S. Exton reports purchases totaling 30,064 common shares on November 6, bringing his direct holding to 328,496 shares.
Nov 5, 2026
Lexicon Pharmaceuticals reports third quarter 2026 financial results and provides clinical updates
Lexicon reported total revenues of $11.3 million for the third quarter of 2026, compared with $14.2 million a year earlier, and a net loss of $14.0 million, or $0.03 per share. Enrollment was completed in the Phase 3 SONATA-HCM study with 542 patients, and topline results are expected in the first quarter of 2027. The company had $183.2 million in cash and investments as of September 30, 2026.
Oct 23, 2026
SONATA-HCM baseline describes 542 patients
The randomized population includes 440 non-obstructive and 102 obstructive HCM patients, with mean baseline KCCQ-CSS of 59. These are baseline characteristics rather than efficacy results; topline remains guided to Q1 2027.
Oct 21, 2026
Sotagliflozin preclinical research published
Company-funded investigator studies describe HCM-model findings and effects on platelet activation and thrombosis in ex vivo and animal work. These are preclinical findings, not SONATA-HCM efficacy results.
LXRX catalyst calendar
- October 21, 2026 — Lexicon highlighted two preclinical publications. Reported · research announcement
- October 23, 2026 — Lexicon released baseline characteristics from SONATA-HCM. Reported · company release
- November 5, 2026 — Quarterly results and filing, updated ZYNQUISTA timing and FMR ownership amendment. Reported · results · 10-Q · Schedule 13G amendment
- November 9, 2026 — The company released its American Heart Association poster results, and a Form 4 disclosed the November 6 purchase by the chief executive. Reported · research announcement · Form 4
- First quarter of 2027 — Pivotal SONATA-HCM topline results and intended ZYNQUISTA NDA resubmission. Company guidance · November 5 update
- First quarter of 2027 — Previously projected completion window for the Phase 1 LX9851 study led by Novo Nordisk. Timing reported by Lexicon in August · August update · November status
- June 1, 2027 — Initial start date of the Hercules minimum-cash covenant under the disclosed terms. Contractual, subject to extension or waiver conditions · Note 6
Three routes for sotagliflozin
U.S. commercial use
INPEFA is approved in cardiovascular care. Label and domestic sales.
Hypertrophic cardiomyopathy
SONATA-HCM is the pivotal trial in symptomatic disease. Endpoint and design.
Type 1 diabetes
ZYNQUISTA remains investigational in the United States. Safety and resubmission.
Lexicon Pharmaceuticals deep dive: the full analysis
The chapters follow Lexicon’s three ways of generating cash: product sales, development milestones and financing. They also explain what the next evidence could change about each route. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios
Bull case
SONATA-HCM demonstrates a meaningful improvement in symptoms across the population it enrolled, with safety and tolerability that support a plausible use in practice. Lexicon submits its ZYNQUISTA application and the agency accepts the package for review. The business then has a clinical basis for a new cardiovascular use and a separate regulatory path for its diabetes indication. An encouraging readout would also raise practical questions about sales coverage, competitive positioning and spending to prepare for a launch. A new use has more commercial significance if Lexicon can reach the relevant patients without taking on obligations that consume much of the potential return.
With a better defined domestic strategy, the Novo Nordisk and Viatris licenses could complement higher INPEFA sales. A future Novo Nordisk payment would reflect a contracted milestone and help support spending. Viatris could add markets in which it secures authorization and converts it into sales. Implementation would still require execution: collecting a milestone, receiving product revenue and converting operating profit into cash are three different events. See development rights and payments and quarterly results.
Base case
Trial data and the regulatory filing arrive around the expected period, but each leaves open what the company can do next. For SONATA-HCM, clinicians and regulators may focus on the magnitude of the symptom change, adverse events and whether effects look similar across disease types. For ZYNQUISTA, the filing may clarify whom Lexicon is seeking to treat without resolving the regulator’s safety assessment. Management has to decide how much to spend while those decisions remain open. Current INPEFA sales and contractual payments help finance the work, while the timing of future milestone receipts remains uncertain.
In this case the company can remain clinically active while depending on a substantial cash and investment balance. Spending could shift from trial conduct to regulatory work or preparations for a broader launch. A decline in one research category would mean little on its own if commercial preparation and financing costs rise. The most useful evidence would be a dated operating plan with a clearer sense of which expenses a partner bears and which Lexicon funds directly. See cash and spending and Hercules debt terms.
Bear case
SONATA-HCM misses the primary endpoint or produces a symptom result whose magnitude or safety leaves little room for a new indication. The diabetes program encounters a further delay or an unfavorable view of its safety package. At the same time, the existing approved product contributes little incremental cash and Novo Nordisk takes longer to reach the next milestone that triggers a payment. Combined, those developments would turn the focus from launch potential to what Lexicon can fund and for how long. More debt would add interest and covenants, while more equity would spread any later success over additional shares.
Each adverse outcome could occur independently. A setback in hypertrophic cardiomyopathy would limit the drug’s prospects for that indication and leave the diabetes application to proceed on its own evidence. A change in partner priorities would affect the timing and likelihood of collaboration payments even if Lexicon’s own trials continued. The risk compounds if several clocks move against the company and it needs capital at the same time. The exposure falls differently on creditors and common shareholders. See debt and the share base.
What would falsify this reading
The thesis depends on product sales remaining too small to define the financial path over the next several quarters. Consecutive periods of substantially higher INPEFA revenue, with comparable or lower commercial expense and a sustained improvement in collections, would challenge that assumption. A larger shipment or one unusually low expense quarter would carry less weight. The clearest signal would come from a change the company can explain in terms of prescribing, volume, access or pricing and that shows up in the cash it retains.
A convincing SONATA-HCM result would narrow the questions about what the molecule can do in this disease. The comparison to placebo needs to be interpretable alongside symptom changes from baseline and the reasons people stop treatment or leave the trial. Evidence that patients notice meaningful improvements, with a consistent result across relevant clinical groups and a manageable safety profile, would strengthen the case for funding a subsequent launch. A disclosed topline figure starts that assessment. A more complete clinical account would inform how broadly it applies. SONATA-HCM study record.
A decision from the U.S. Food and Drug Administration (FDA) would offer the clearest test of the ZYNQUISTA case. Meeting an agreed exposure requirement can improve the package. The strength of that package will depend on how the agency interprets the risks in the proposed population, the monitoring approach and the evidence of benefit. An agency decision with a defined eligible population would offer far more information for a commercial model than the month in which the company submits the application. A fixed review date, if announced, would only answer the scheduling question. Prior FDA response reported by Lexicon · Current company plan.
The financing view would change if the company secures a partner responsible for significant clinical expense or receives recurring product and royalty cash that supports its plan. An agreement would have to be read for rights ceded and conditions retained. Upfront cash with assigned costs can change near-term liquidity, while future performance payments only enter the analysis when the relevant events become sufficiently concrete. Paying for a longer development interval can be worthwhile if the structure preserves enough economics of a successful outcome.
02 How Lexicon’s portfolio earns revenue
Lexicon Pharmaceuticals develops medicines for chronic disease, with current priorities in cardiovascular and metabolic conditions and a separate neuropathic pain candidate. Chief Executive Officer Michael S. Exton and Senior Vice President and Chief Financial Officer Scott M. Coiante signed the filing for the September quarter. Under its reporting structure, the business operates as a single segment. That means the product operation, licensing relationships and clinical portfolio share one set of financial statements. Decisions about which trials to finance are visible mainly through spending commentary and agreement terms. Form 10-Q, segment reporting and signatures.
Sotagliflozin inhibits sodium-glucose cotransporters 1 and 2. Lexicon sells it in the United States as INPEFA under a label tied to cardiovascular events, and is seeking separate uses in hypertrophic cardiomyopathy and glycemic control in type 1 diabetes. The label and evidence for each intended population define the company’s commercial opportunity. The same active ingredient can support several prospects while tying part of the portfolio to a shared molecule and its safety characteristics. INPEFA prescribing information · Company pipeline update.
The pipeline also includes LX9851, an oral investigational compound in development for obesity and associated disorders under a worldwide license to Novo Nordisk, and pilavapadin, an investigational non-opioid pain candidate. Novo’s control over development shifts costs and execution to the partner while making milestone timing less directly observable to Lexicon shareholders. Pilavapadin leaves a different choice: the path to registration can bring direct development costs or a need to agree with a partner on who pays for them. Programs and corporate priorities · Note 5, collaborations and strategic alliances.
03 Which events can change the outlook
The first pivotal SONATA-HCM results are the main clinical milestone Lexicon expects in the near term. Lexicon described its first-quarter 2027 topline expectation on November 5 after completing enrollment. A topline release can confirm the primary endpoint result before providing all the safety, discontinuation and subgroup information needed to judge the application prospects. A clinical success would therefore change the discussion before it defines the approved use, a commercial timetable or the eventual size of the eligible population. November 5 update.
The August 6 results release pointed to the fourth quarter of 2026 for a ZYNQUISTA resubmission. On November 5 the company moved its expectation to the first quarter of 2027, with data preparation and administrative work under way. The new target replaces the earlier window. Because this is a regulatory submission, its first observable outcome will be whether a completed package is submitted. A company announcement of FDA acceptance or an agency action date would come separately if the application proceeds. Earlier company timing · Current company timing.
Novo’s first human study of LX9851 was ongoing in the November update. Lexicon had previously given a first-quarter 2027 completion window. Completion of study activities, a public readout and a financial milestone can fall on different dates. Public expectations should account for the partner’s communication and control over timing. A Phase 1 report may describe tolerability and drug exposure in a way that helps design later studies without measuring durable clinical benefit. August company update · November program status.
On November 11 Lexicon announced its planned November 18 appearance at the Jefferies Global Healthcare Conference in London. Such a discussion can clarify management’s priorities and use of resources. The announcement did not specify a clinical result or regulatory filing for the event. The next reported quarter will also matter for understanding product revenue, spending after SONATA enrollment and how far licensing cash receipts offset those expenses. As of November 17 the company had yet to announce the date of its next earnings report. Conference notice · Company releases.
04 INPEFA and the domestic sales test
The FDA approved INPEFA in May 2023. Its label covers reduction of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure or with type 2 diabetes, chronic kidney disease and additional cardiovascular risk factors. That breadth still leaves a commercial challenge: clinicians already have cardiovascular and diabetes regimens they know, and an eligible patient and a prescription are separate measures of adoption. The label identifies the population the drug can serve. The accounts show the contribution it currently makes. FDA-approved prescribing information.
Lexicon’s September-quarter net product revenue was $1.181 million, up from $1.008 million in the comparable 2025 quarter. Net product revenue for nine months was lower than the prior year, as the table in the financial chapter shows. Those two comparisons give a more useful picture of direction than focusing on a single quarterly increase. For a commercialization decision, the revenue base must be considered alongside selling expense, the cost of reaching prescribers and the resources the company would need to support a new use. Net product revenue in the consolidated statements.
The initial product cost base also merits caution. Lexicon disclosed that it received certain materials at zero cost or expensed them during research and development before approval. Cost of sales therefore includes the effect of materials whose original production costs were already expensed or were borne elsewhere. As new inventory replaces those materials, reported product costs could move even if commercial operations improve. Lexicon estimated that the remaining zero-cost materials represented roughly $20 million at current manufacturing costs. It projected cost of goods sold below 10 percent of net product revenue after those materials are consumed. The manufacturing-cost estimate is separate from inventory carrying value. The present financial statements do not provide the basis for projecting a steady-state product gross margin from the reported cost of sales alone. Management’s discussion of cost of sales and inventory.
INPEFA is already a route to domestic revenue, which distinguishes it from the development candidates. Its contribution to the company’s economics remains a question of scale, adoption and cost. Broader use of a new indication, if authorized, could change the size and mix of the commercial operation. A meaningful forecast still needs to account for what that use would cost to support and how much cash it could generate after paying for distribution, selling efforts and existing programs.
05 SONATA-HCM and the symptom endpoint
Hypertrophic cardiomyopathy (HCM) can limit what people are able to do and diminish their quality of life. Some patients have obstruction to blood flow out of the left ventricle and others have symptomatic disease without that obstruction. SONATA-HCM enrolled patients in both groups. A single study spanning them can ask whether people report better symptoms across the overall group. A separate question is how large and consistent the effect is within each group, which may matter to clinicians considering individual patients. The study’s design and the announced analysis should guide any comparison between groups. Study design and outcome measures.
Lexicon disclosed 542 enrolled participants and a mean baseline Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) of 59. Of the 542 participants, 440 had non-obstructive disease and 102 had obstructive disease. The protocol permitted stable background treatment, including cardiac myosin inhibitors. The score combines symptoms and physical limitations. The figure of 59 describes people at entry and gives context for the symptom burden the study is attempting to improve. It provides no after-treatment comparison. At week 26, the primary endpoint compares changes from baseline in KCCQ-CSS between treatment and placebo across the study population. The company’s actual enrollment disclosure postdates an earlier registry entry showing a planned target of 500. October 23 baseline disclosure · ClinicalTrials.gov study record.
For the first-quarter readout, the starting point is the difference between arms and the uncertainty around it. The outcome also needs enough context to say whether the benefit would matter to a symptomatic patient. That context could include absolute changes in each group, estimated effect size, the distribution of responses and the safety information available. Discontinuations and missing questionnaires can affect interpretation, especially when a study looks at symptoms reported by patients rather than only at a laboratory measure. Data from a trial enrolling both major forms will be most useful if the results clarify how broadly the overall finding applies. Registered primary and secondary endpoints.
On October 21 Lexicon highlighted two preclinical publications on sotagliflozin. One examined cardiac function and structure in an animal model of HCM. The other studied platelet activation and thrombus formation in blood outside the body and in animal models. These experiments addressed mechanisms. October 21 research announcement.
On November 9 Lexicon released two sets of findings presented at the American Heart Association Scientific Sessions. In a randomized crossover study of 15 healthy adults, blood was assessed outside the body under conditions designed to resemble arterial and venous flow. Lexicon reported reductions from baseline of 11.9 percent and 15.6 percent in modeled clot formation with sotagliflozin in those conditions. The reported statistical comparisons were against baseline, and the company said the reductions with empagliflozin in the same study did not reach statistical significance. Clinical events and any difference from another drug would require evidence suited to those questions. November 9 scientific update.
The second poster measured myocardial work in slices of living heart tissue from patients with HCM. The company described acute reductions in myocardial work with sotagliflozin and empagliflozin and greater potency for sotagliflozin at higher afterload in that experiment. This is a tissue model. Differences observed there help explain what researchers are studying and do not predict how patients will score after months of treatment. The pivotal trial is the source for clinical evidence on symptoms and physical limitations. Heart tissue findings · Registered trial endpoints.
06 ZYNQUISTA, ketoacidosis and the filing path
Lexicon’s separate application for ZYNQUISTA proposed adding sotagliflozin to insulin for glycemic control in adults with type 1 diabetes and chronic kidney disease. Lexicon announced receipt of an FDA Complete Response Letter (CRL) on December 20, 2024. A CRL communicates that the FDA cannot approve an application in its present form. Lexicon had received an earlier complete response in March 2019. The company says the proceeding tied to the FDA’s 2021 notice of opportunity for a hearing remained open. In the December 2024 letter, the FDA found the benefit-risk balance insufficient for the proposed population and cited unresolved concerns about ketoacidosis. FDA December 2024 letter · 2021 notice · September-quarter filing. The commercial availability of INPEFA for its cardiovascular indication does not resolve the safety and benefit questions for the type 1 diabetes population. December 20, 2024, company announcement · Current U.S. INPEFA label.
Diabetic ketoacidosis (DKA) is central to the benefit-risk assessment. A glycemic measure may improve while a rare and serious safety event remains an important concern. How often events occur, how they are identified and how closely patients can be monitored are relevant to an eventual label. The FDA’s INPEFA prescribing information identifies ketoacidosis warnings and additional risk in patients with type 1 diabetes. The application and the current label have separate regulatory histories. The European Commission withdrew the prior European Union marketing authorization for ZYNQUISTA in March 2022 at the holder’s request, with the withdrawal tied to commercial reasons according to the regulator. FDA label safety section · European authorization history.
STENO1 is an investigator-led Danish study of a multifactorial intervention in type 1 diabetes. The study evaluates a care approach rather than isolating sotagliflozin as its sole difference between groups. On November 5 Lexicon said the study had met the patient-exposure and safety-data requirements agreed with the FDA to support resubmission. It described low rates of DKA comparable to standard care and said the evidence complements the earlier inTandem Phase 3 program. That is the sponsor’s assessment of the available safety data. The study registry provides context for which comparisons the design can support. STENO1 design · Company statement on the FDA package.
A resubmission is a concrete administrative step. Lexicon can assemble the response, submit it and communicate what it has included. FDA will decide whether it is adequate for review and what issues remain. The biggest commercial uncertainty is the eventual eligible population and the terms under which patients could receive the product. In an indication where risk management matters, a label could shape clinical adoption and commercial expense as much as the number of patients with the underlying condition. For the timing distinction see milestones.
07 Novo Nordisk, Viatris and pilavapadin
Under the March 2025 agreement, Novo Nordisk has exclusive worldwide rights to develop, manufacture and commercialize LX9851. The candidate is an oral investigational inhibitor of acyl-CoA synthetase 5 (ACSL5) for obesity and related metabolic disorders. Novo started Phase 1 in March 2026. The disclosed design studies single and multiple ascending doses against placebo in people who are overweight or have obesity. Early human work can tell the sponsor whether exposure and tolerability justify later development. It would take additional studies to show clinically meaningful and durable weight or health outcomes. Note 5 license terms · LX9851 study status.
The agreement produced $45 million upfront in April 2025 and three $10 million development milestone receipts in 2026: two in the first half of the year and a third in the third quarter. Lexicon announced achievement of the third, tied to a patient dosing milestone, on August 24. The company has therefore earned $75 million from upfront and achieved development milestones. The contract provides for up to $455 million more in specified regulatory and commercial launch milestones and up to $475 million in specified sales milestones, in addition to tiered royalties from single-digit to low-double-digit percentages of annual net sales, subject to reductions. Future milestone amounts become due only if the milestones occur. August milestone announcement · Payment dates and remaining conditional amounts.
The main advantage of that structure is that Lexicon can participate in the program without funding the same work directly. The tradeoff is control of execution and disclosure. Novo can decide what to prioritize within its portfolio and when to advance or communicate the program under the agreement. The near-term financial exposure is to the next qualifying milestones and to the cost Lexicon bears in the meantime. The long-term exposure depends on program success and future sales. Neither the contract ceiling nor the fact that three milestones were paid provides a schedule for the remaining payments.
Viatris licenses commercial and development rights to sotagliflozin outside the United States and Europe under an October 2024 agreement. Lexicon received $25 million upfront. Up to $12 million of regulatory milestones and $185 million of sales milestones remain contingent. The agreement also provides low-double-digit to upper-teens royalties on annual net sales in the licensed territory, and a separate supply agreement sets a transfer price. The economic benefit of supplying product and the benefit of earning a royalty should be kept distinct. Note 5, Viatris license and supply agreement.
Lexicon said on November 5 that Viatris had obtained heart-failure approvals in the United Arab Emirates and Bahrain and submitted applications in other markets. An international approval can expand the licensed opportunity, and its value to Lexicon depends on local launches, demand, supply and the royalty calculation. A pending application concerns a separate country decision. Comparing the same status across countries is more informative than counting all approvals and applications as if each produced revenue today. November 5 international status.
Pilavapadin is in development for diabetic peripheral neuropathic pain. The Phase 2b PROGRESS study enrolled 496 participants and missed its prespecified dose-response primary endpoint at week 8. Lexicon said results at a single dose helped it select the proposed Phase 3 dose and reported that FDA raised no objection to the proposed program. The company outlined two placebo-controlled studies using change in average daily pain at week 12. The FDA feedback gives Lexicon a clearer basis for planning the proposed trials. The September-quarter filing says Lexicon needs additional funding to conduct the Phase 3 program. The costs, start dates and new efficacy data remain to be established. Lexicon has also explored obesity in preclinical work, a stage earlier than the neuropathic pain program. The 10-Q discloses a $5 million milestone owed to Bristol Myers Squibb if the first Phase 3 patient is dosed. That payment belongs in a funding plan for starting Phase 3. Phase 2b PROGRESS results · Pilavapadin development update · Commitments disclosed in the 10-Q.
08 September-quarter results and revenue mix
The financial statements distinguish net product sales, licensing and milestones, and royalties or other revenue. Lexicon recognized the third Novo development milestone in its third-quarter 2026 results. Lower year-over-year total revenue combined with higher quarterly INPEFA sales is therefore consistent with the change in revenue mix. Figures below are in thousands of U.S. dollars except loss per share. Weighted-average shares are stated in thousands. Form 10-Q, consolidated statements of comprehensive loss.
| Reported line | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Net product revenue | 1,181 | 1,008 | 2,951 | 3,592 |
| Licensing and milestones | 10,000 | 13,154 | 30,000 | 40,698 |
| Royalties and other revenue | 69 | 20 | 93 | 20 |
| Total revenue | 11,250 | 14,182 | 33,044 | 44,310 |
| Cost of sales | 79 | 10 | 226 | 73 |
| Research and development | 16,204 | 18,757 | 46,403 | 49,806 |
| Selling, general and administrative | 9,462 | 7,602 | 28,446 | 28,562 |
| Total operating expenses | 25,745 | 26,369 | 75,075 | 78,441 |
| Loss from operations | (14,495) | (12,187) | (42,031) | (34,131) |
| Loss on early debt extinguishment | — | — | (4,349) | — |
| Net loss | (14,005) | (12,769) | (46,823) | (34,811) |
| Loss per share, basic and diluted | (0.03) | (0.04) | (0.11) | (0.10) |
| Weighted-average shares, basic and diluted | 444,956 | 363,399 | 427,780 | 362,927 |
Research spending declined from the comparable quarter as external costs fell following completion of the earlier pilavapadin work. Higher Phase 3 spending on SONATA-HCM partly replaced those costs. Selling, general and administrative expense rose, with the company citing higher employee benefits and pre-commercialization expense in the results release. The movement between categories offers a better guide to likely costs than an assumption that spending will drop once a trial enrolls its last patient. Programs continue to require follow-up, analysis and preparation for next steps. Operating expense discussion · Company commentary.
In its November 5 results presentation, Lexicon projected full-year 2026 operating expenses of $100 million to $110 million, with $63 million to $68 million of research and development excluding Phase 3 pilavapadin costs, and $37 million to $42 million of selling, general and administrative costs including targeted pre-commercialization work. These figures describe the operating expense plan. Cash receipts and noncash charges also affect the amount of money operations use. November 5 results presentation.
The September net loss increased even though loss per share declined by a cent from the prior-year quarter. The weighted-average number of shares was materially larger, changing how the loss translated into the reported per-share measure. The nine-month loss also includes the extinguishment charge from closing out the earlier loans. That charge and the larger equity base affect financial comparisons in different ways. It is useful to start with operating performance before moving to financing costs and per-share results. Financial statements and debt note.
09 Liquid assets and operating use
Lexicon ended September with $44.081 million in cash and equivalents and $139.122 million in short-term investments. Together they amounted to $183.203 million. The investment portfolio consisted of U.S. Treasury securities and corporate debt securities, with the company describing maturities of three to 12 months at purchase. The short-term investments are part of available resources under the company’s operating plan. The cash flow statement reports a narrower ending balance because it tracks cash and equivalents rather than securities classified as investments. Balance sheet, investment note and cash flow statement.
At December 31, 2025 the balance sheet showed $34.326 million of cash and equivalents, $61.904 million of short-term investments and $29 million of restricted cash. The old restriction ended with repayment of the Oxford loans. At September 30, 2026, the restricted cash line was zero. That change affected availability and the comparison to the year-end total. A valid comparison should keep the earlier restricted balance distinct while recognizing that the February financing and subsequent cash use also changed the balance. Comparative balance sheet and Oxford loan disclosure.
Operating cash use was $32.001 million in the first nine months of 2026 against $50.618 million in the first nine months of 2025. Internal spending and external milestone receipts both affect that measure. The 2026 figure includes the cash effects of received development milestones and changes in receivables, inventories and payables. It is therefore sensitive to the timing of partner payments. An investor assessing the next several quarters should allow for periods with fewer receipts or more spending even when the clinical schedule is moving according to plan. Cash flow statement and licensing note.
Investing activities used $75.543 million, principally as purchases of investments exceeded maturities. Net financing cash provided was $88.299 million. Cash that is placed in short-term securities moves into the investing category while remaining in liquid financial assets. By contrast, a research expense typically consumes resources to advance a program. The distinction explains how Lexicon could report less cash and restricted cash while ending the period with a larger pool of cash and short-term investments. Investing and financing activities.
The November 5 Form 10-Q says existing unrestricted liquidity together with anticipated cash and revenues from collaborations and other sources should fund planned operations for at least the next 12 months. Management’s assessment is tied to the current plan and expected receipts. Future changes in enrollment, trial scope, development rights and commercial preparations can alter the cost base. The disclosed cash and investment balance gives the company choices about when to fund the work. The pace and timing of those choices will shape financing requirements beyond the plan. Liquidity outlook and its assumptions.
10 Hercules credit and the cash covenant
Lexicon replaced its Oxford loans with a Hercules Capital facility in May 2026. The new agreement provides for up to $100 million across three tranches and funded $55 million at closing. Remaining capacity consists of $20 million subject to performance milestones and timing restrictions, with June 15, 2028, as the latest draw date, and $25 million subject to the lender’s consent before the interest-only period expires. At September 30, the net carrying amount of long-term debt was $51.894 million. That carrying value reflects deductions including issue costs and discounts and is distinct from funded principal. None of the $45 million of unfunded capacity is included in the September liquidity figure. Note 6, multiple tranches and debt carrying value.
The loan bears interest at prime plus 3.10 percentage points with a 9.85 percent floor. The stated rate at September 30 was 10.10 percent. Interest-only payments run for an initial 18 months, with potential extensions to 24 or 30 months if the performance tests are met. The agreement then calls for amortization through maturity in May 2030. A final payment equals 6.25 percent of funded amounts, and contractual prepayment fees start at 3 percent of principal repaid and decline on the contract schedule. The effective cost of borrowing therefore extends beyond the cash coupon. Hercules interest and payment terms.
Hercules has a first lien over the assets. The agreement initially calls for a minimum-cash covenant starting June 1, 2027, subject to a contractual extension to January 1, 2028 if specified performance milestones are met and to waiver under specified conditions. A minimum product-revenue covenant may begin at specified times after either later tranche is drawn, with separate waiver conditions. Lexicon reported compliance at September 30. The timing matters because a new draw can bring both cash and additional constraints. Equity shareholders should look at what becomes binding when the terms of each tranche are met. Note 6, restrictive provisions and covenants.
In May Lexicon repaid $54.3 million under the Oxford loans including prorated exit fees. The company recorded an early extinguishment loss and released the earlier minimum restricted-cash requirement. That refinancing helped free cash but replaced one creditor obligation with another. The new warrants, discussed in the next chapter, also give Hercules a route to equity participation. The debt note describes the capacity and accounting treatment, while the cash flow statement shows the timing and amount of repayments and proceeds. Oxford repayment and financing cash flows · Warrants and share issuance.
11 Financing, awards and dilution
Lexicon reported 445,234,571 common shares outstanding as of November 2, 2026, on the cover of its Form 10-Q. The balance sheet also presents common shares issued and treasury shares, categories whose dates and meanings differ from the cover-page figure. During February the company raised cash in a public offering and a concurrent private placement. The public deal sold 34,089,403 shares at the offering price of $1.30 a share for approximately $40.6 million of net proceeds after expenses. The size of that transaction helps explain the change in the equity denominator against 2025. Form 10-Q cover and Note 9.
Invus-related entities purchased 22.4 million common shares at $1.30 and 408,434.70 shares of Series B convertible preferred stock at $65 per preferred share in the concurrent placement. The April charter amendment increased authorized common stock from 450 million to 900 million shares. When the conditions for conversion were satisfied, those preferred shares converted into 20,421,735 common shares. The September balance sheet listed no preferred shares outstanding. The February financing generated about $96.2 million net as described in management’s discussion, and the later conversion changed the form of securities already purchased. Private placement and Series B conversion disclosures.
The December 2023 at-the-market agreement with Jefferies left $75 million of issuance capacity available at September 30. Capacity sets a limit on eligible sales under the agreement. Cash arrives only after shares are sold, with the number of shares depending on the realized terms. The August 6 Form S-3 registered up to 1,257,856 common shares underlying warrants for resale by the selling stockholders, including shares tied to conditional future draws. It became effective August 14. Lexicon receives no proceeds from the resale. A cash exercise of the warrants could bring proceeds separately. Open Market Sale Agreement disclosure · August resale registration · Notice of effectiveness.
The company reported 24.944 million options outstanding at September 30 at a weighted-average exercise price of $1.81, including 12.150 million exercisable at a weighted average of $2.47. It also reported 15.101 million restricted stock units (RSUs) outstanding with weighted-average grant-date fair value of $1.09. Grant-date value is an accounting measure for the awards. The number of shares ultimately issued for outstanding awards will vary with vesting, forfeitures and option exercise. The company also used treasury stock to satisfy some vesting during the period. Note 8, stock option and RSU activity.
Hercules received warrants for 691,823 shares at a contractual exercise price of $1.59 with the first draw. Warrants for 251,572 and 314,465 more shares are conditional on funding the second and third tranches respectively. Those conditional instruments are separate from the warrants already issued. Individual sources of potential dilution differ in timing and probability. A cash financing, vesting of employee awards and a new warrant issued with borrowing can each increase exposure without occurring in the same period. Note 6, warrants issued and conditional on later draws.
12 Ownership and short interest
In its November 5 Schedule 13G amendment, FMR LLC reported beneficial ownership of 66,743,389.66 common shares, or 15.0 percent, at September 30. The 29,155,748 shares reported by the Fidelity Growth Company Commingled Pool, or 6.6 percent, are included in FMR’s reported holdings. Adding that block to the group total would overstate the position. The filing describes powers and reported holdings at a date, while a subsequent filing may reflect a different share count or position. November 5 FMR ownership amendment.
The May 8 Invus and Artal Schedule 13D amendment identifies a collective holding of 227,034,705 shares, or 51.1 percent, using the company’s outstanding count at May 4. The filing also identifies the directly held Artal Participations position of 175,156,062 shares, or 39.4 percent on that base. The positions cannot be added across reporting parties who share beneficial ownership. The concentration matters for how shareholders assess voting power and future equity transactions. A dated report gives ownership at the stated denominator and does not replace a fresh reconciliation if more shares are issued. Invus and Artal ownership amendment.
Chief Executive Officer Michael S. Exton reported purchases totaling 30,064 shares on November 6 in a Form 4 filed November 9. Transaction code P identifies an open-market or private purchase, and the filing gives a weighted-average transaction price of $1.6631. It shows 328,496 shares held directly after the trade. November 9 Form 4.
At the October 30 settlement, Nasdaq reported 25,877,882 shares short, average daily volume of 1,843,171 shares and 14.04 days to cover. Days to cover compares the dated position with average trading volume. It can be elevated when the short interest is large, when average volume is low or when both conditions apply. It is a way to describe trading conditions for a historical reporting period, and does not tell when a position will be covered or how the market will react to clinical data. Nasdaq short-interest history.
13 Risk, commitments and what can support value
The business has several obligations linked to reaching milestones. The 10-Q discloses $4.5 million of royalty payments in three annual installments if sotagliflozin receives type 1 diabetes approval in a major market, as well as the separate Bristol Myers Squibb payment at the start of Phase 3 dosing for pilavapadin. It also reports an operating lease liability of $7.644 million in present-value terms. Ordinary-course claims and proceedings are described in Note 7, where management says it expects no material adverse effect individually or in aggregate. These obligations and disclosures affect the risk picture in ways distinct from trial results. Note 7 and other commitments in the 10-Q.
The equity case depends on what the company can build with the capital already raised. The near-term readout can answer a question about symptoms in HCM. The diabetes submission could reveal what Lexicon proposes after another round of safety work. Novo’s next decision will offer evidence about an early partnered asset. Those disclosures would leave different paths to future cash, and their order matters. A favorable clinical result can improve one path while a weak commercial quarter or an expensive financing reduces the share of its value that remains for existing holders.
Improving product revenue, containing spending and preserving favorable economic terms in its partnerships would each make development more valuable to shareholders. On the other hand, a company can use its liquidity to reach an informative decision and still remain dependent on further financing. A careful assessment should watch how financial capacity changes after the clinical and regulatory events, because the usability of a new product and the resources needed to bring it to market are separate parts of the investment case.
Merlintrader Health Score · $LXRX
3.15out of 5
Assessed November 18, 2026. Merlintrader calculation: 3.5 × 30% + 4.0 × 30% + 2.0 × 20% + 2.5 × 10% + 2.5 × 10% = 3.15 out of 5.
LXRX red flags
- Clinical readout and filing are different tests. SONATA-HCM efficacy and the ZYNQUISTA safety package need their own evidence. See the pivotal study and the diabetes application.
- Milestone-driven revenue. The collaboration payment dominated the quarter while nine-month domestic product revenue declined. See the reported revenue mix.
- Debt restrictions and equity capacity. Hercules covenant dates and the Jefferies agreement can shape how Lexicon funds a longer development timeline. See credit terms and share issuance.
LXRX Stock FAQ: Lexicon Pharmaceuticals Questions Answered
When will Lexicon report SONATA-HCM topline results?
As of November 17, 2026, Lexicon expected SONATA-HCM topline results in the first quarter of 2027, with no specific date announced. The company also plans to resubmit the separate ZYNQUISTA application in that quarter. November 5 guidance.
Is Lexicon’s ZYNQUISTA FDA approved?
As of November 17, 2026, ZYNQUISTA remained investigational in the United States for type 1 diabetes. INPEFA also contains sotagliflozin and has a separate cardiovascular indication. In December 2024, Lexicon announced that it had received a Complete Response Letter from the FDA for the diabetes application. Company announcement on the FDA response · INPEFA label.
How much cash does Lexicon have, and how long could it last?
Lexicon had $183.203 million in cash and short-term investments at September 30, 2026. In its November 5 filing, the company estimated that current liquidity and anticipated receipts would fund operations as planned for at least the following 12 months. Balance sheet and liquidity outlook.
Is LXRX stock at risk of dilution?
Yes. Lexicon reported outstanding options, restricted stock units and lender warrants as of September 30, 2026, and its at-the-market agreement had $75 million of capacity available at that date. The common share count was 445,234,571 on November 2, 2026. Form 10-Q and equity notes.
When does Lexicon Pharmaceuticals report earnings?
As of November 17, 2026, Lexicon had not announced its next earnings date. Its latest results, released November 5, covered the quarter ended September 30, 2026. The results chapter shows how product sales and partner milestones contributed. November 5 results · Company investor events.
What does Lexicon Pharmaceuticals do?
As of November 2026, Lexicon develops medicines for serious chronic conditions and commercializes INPEFA in the United States. Its pipeline includes studies of sotagliflozin in other conditions and a partnered early-stage candidate for obesity. It also has a neuropathic pain program.
Sources
- Form 10-Q for the quarter ended September 30, 2026 · November 5, 2026, results exhibit · Lexicon news releases
- Current FDA INPEFA label · ZYNQUISTA complete response announcement · European marketing history · STENO1 study design
- SONATA-HCM trial record · SONATA baseline announcement · November 9 scientific update · November 11 Jefferies conference notice
- Third Novo development milestone · August company update · August resale registration · Notice of effectiveness
- Invus and Artal Schedule 13D amendment · FMR Schedule 13G amendment · Form 4 for Michael S. Exton · Nasdaq settlement history
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $LXRX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies face clinical, regulatory and commercial risk. Safety findings, delays in approval, limited use of an approved therapy, production costs and the need for additional financing can lead to investment losses. Lexicon faces material dependence on clinical results, future FDA decisions and contingent development payments. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



